Marty Toomajian: Battelle, ExThera Partner to Develop Sepsis Treatment Device

Battelle, ExThera Medical and NxStage Medical have collaborated to develop a medical device for treating sepsis under a contract with the Defense Advanced Research Projects Agency.

Battelle will work to review the safety and efficacy aspects of ExThera’s Seraph Microbind Affinity Blood Filter as part of the Dialysis-Like Therapeutics device program, Battelle said Wednesday.

“Battelle is excited to have ExThera join our team to develop a DLT device to treat sepsis in warfighters,” Marty Toomajian, president of Battelle energy, health and environment sector.

Toomajian  added that ExThera’s Seraph technology and blood separation systems from other DLT developers “are needed to meet DARPA’s aggressive program requirements.”

DARPA’s DLT program, initiated in 2010, aims to develop a system capable of eliminating “dirty” blood and harmful agents from the body using filter technologies.

NxStage will manufacture the DLT system and the other DLT developers will supply blood separation filters for use in the system.

DARPA will submit an investigational device exemption to the Food and Drug Administration prior to the DLT system’s transition to clinical trials.